^
    Back
    Association details:
    Biomarker:MUC16 mutation
    Cancer:Melanoma
    Drug Class:Immunotherapy
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    JAMA Netw Open
    Title:

    Association of MUC16 Mutation With Response to Immune Checkpoint Inhibitors in Solid Tumors

    Published date:
    08/03/2020
    Excerpt:
    Both NSCLC and melanoma cohorts included ICI-treated patients...MUC16 mutation was associated with improved overall survival in both the NSCLC (hazard ratio, 0.34; 95% CI, 0.12-0.99; P = .04) and melanoma (hazard ratio, 0.57; 95% CI, 0.36-0.90; P = .02) cohorts.
    DOI:
    10.1001/jamanetworkopen.2020.13201